AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526670: Methyl triacetylcholate

Chemical compound data from PubChem database. IUPAC Name: methyl 4-(3,7,12-triacetyloxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate. Molecular Formula: C31H48O8. Molecular Weight: 548.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525264: N'-(1-naphthyl)-N,N-dimethyl-formamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-naphthalen-1-ylmethanimidamide. Molecular Formula: C13H14N2. Molecular Weight: 198.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Fibroblast biology: Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis

There is growing evidence that activated synovial fibroblasts, as part of a complex cellular network, play an important role in the pathogenesis of rheumatoid arthritis. In recent years, significant progress has been made in elucidating the specific features of these fibroblasts. It has been understood that although macrophage and lymphocyte secreted factors contribute to their activation, rheumatoid arthritis synovial fibroblasts (RA-SFs) do not merely respond to stimulation by pro-inflammatory cytokines, but show a complex pattern of molecular changes also maintained in the absence of external stimulation. This pattern of activation is characterized by alterations in the expression of regulatory genes and signaling cascades, as well as changes in pathways leading to apoptosis. These together result in the upregulation of adhesion molecules that mediate the attachment of RA-SFs to the extracellular matrix and in the overexpression of matrix degrading enzymes that mediate the progressive destruction of the joints. In addition, activated RA-SFs exert specific effects on other cell types such as macrophages and lymphocytes. While the initiating step in the activation of RA-SFs remains elusive, several key pathways of RA-SF activation have been identified. However, there is so far no single, specific marker for this phenotype of RA-SF. It appears that activated RA-SFs are characterized by a set of specific properties which together lead to their aggressive behavior.
Table 22. Needing But Not Receiving Treatment for Illicit Drug Use in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past year need for but not reciept of treatment for illicit drug use by those aged 12 or older by State and substate regions.
Medication-Assisted Treatment Facility Maps (MAT)

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.For more information on the methodology used by the Center for Behavioral Health Statistics and Quality (CBHSQ) to create this set of state maps showing specific areas (census tracts) that are potentially underserved by medication-assisted treatment (MAT) facilities, please clickhere[PDF 847KB].
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches

Therapeutic options for patients with more severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is accumulating evidence that anti-tumor-necrosis-factor (anti-TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis and psoriatic arthritis. The major anti-TNF-α agents currently available, infliximab (Remicade®) and etanercept (Enbrel®), are approved for the treatment of rheumatoid arthritis (RA) in many countries. In ankylosing spondylitis there is an unmet medical need, since there are almost no disease-modifying antirheumatic drugs (DMARDs) available for severely affected patients, especially those with spinal manifestations. Judging from recent data from more than 300 patients with SpA, anti-TNF therapy seems to be even more effective in SpA than in rheumatoid arthritis. However, it remains to be shown whether patients benefit from long-term treatment, whether radiological progression and ankylosis can be stopped and whether long-term biologic therapy is safe.
NYTD Reviewer Recruitment Flier

This flier, developed in collaboration with National Youth in Transition Database (NYTD) Reviewers, provides information about NYTD, the NYTD Reviews, and recruitment information to prospective NYTD Reviewers. It is available in English and Spanish.

If you are interested in learning more about becoming a NYTD Reviewer, please email the Child Welfare Compliance Reviews Team at cw-mail@jbsinternational.com for additional information, or check out NYTD Reviewer Responsibilities at https://www.acf.hhs.gov/cb/report/nytd-reviewer-responsibilities.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 527273: Pentanoic acid, 4-methyl, 2,2,2-trichloroethyl ester

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl 4-methylpentanoate. Molecular Formula: C8H13Cl3O2. Molecular Weight: 247.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Risk Factor Surveillance Survey: 2013

The Behavioral Risk Factor Surveillance System (BRFSS) is an annual statewide telephone surveillance system designed by the Centers for Disease Control and Prevention (CDC). BRFSS monitors modifiable risk behaviors and other factors contributing to the leading causes of morbidity and mortality in the population. New York State's BRFSS sample represents the non-institutionalized adult household population, aged 18 years and older. Although the overall number of respondents in the BRFSS is more than sufficiently large for statistical inference purposes, subgroup analyses can lead to estimates that are unreliable. Interpreting and reporting weighted numbers that are based on a small, unweighted number of respondents can mislead the reader into believing that a given finding is much more precise than it actually is. The BRFSS follows a rule of not reporting or interpreting percentages based upon a denominator of fewer than 50 respondents (unweighted sample). Both a csv and sas data files are available. For more information, check out http://www.health.ny.gov/statistics/brfss/.
NNDSS - TABLE 1Z. Pertussis to Poliomyelitis, paralytic

NNDSS - TABLE 1Z. Pertussis to Poliomyelitis, paralytic - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Data from California published in week 29 for years 2019 and 2020 were incomplete when originally published on July 24, 2020. On August 4, 2020, incomplete case counts were replaced with a "U" indicating case counts are not available for specified time period. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ The pertussis case definition was modified by CSTE effective January 1, 2020. Criteria were modified increasing sensitivity for case ascertainment such that case counts may increase.
2012 Uniform Reporting System (URS) Tables for Pennsylvania

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Managed Care Individual Provider Network Data: June 30, 2017

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of health plans in New York State. Beginning in 2017, the PNDS includes Medicaid Managed Care (MMC), HIV Special Need Plans (SNP), Health and Recovery Plans (HARP), Child Health Plus (CHP), Programs of All-Inclusive Care for the Elderly (PACE), Non-PACE Managed Long-Term Care (MLTC) plans, Qualified Health Plans (QHP), Essential Plans (EP), and commercial plans (commercial plan reporting will be incomplete until Q2 2017). This dataset reflects individual provider data. Provider Network Data System information is self-reported by health plans. The PNDS data dictionary can be found at http://www.health.ny.gov/health_care/managed_care/docs/dictionary.pdf. To use the NYS Provider & Health Plan Look-Up Tool, click on the following link, https://pndslookup.health.ny.gov/.
Patent AT-E401612-T1: [Translated] CLUSTER TECHNOLOGY FOR CYCLIC PHENOMENA

A data processing system processes data arrays that collectively describe cyclic behavior of at least one variable in several entities in a physical process. Each cycle comprises several time slots. An input routine (2-4) receives multiple data arrays, each data array containing multiple data items, each of which describes a variable of an entity in one time slot. A magnitude-determination routine (2-6) determines a specific magnitude parameter, such as average, volume or peak, for each of the several entities. A scaling routine (2-8) scales the data arrays between entities such that the specific magnitude parameters are suppressed and only their shape is maintained. A training routine (2-10) trains a clustering system with a first plurality of the scaled data arrays, to determine a set of cluster centers. After training, a clustering routine (2-12) applies a second plurality of the scaled data arrays to the trained clustering system.
Patent AT-E399628-T1: [Translated] METHOD AND DEVICE FOR PRODUCING PLATE-SHAPED FIBER-REINFORCED PRODUCTS

A method for making a plate-like fiber-reinforced product to be used as building or packing material, the method comprising: placing fibers on a lower laminate; applying a binding agent on the fibers so that the fibers are surrounded by the binding agent; transferring the fibers with binding agent between the lower laminate and an upper laminate between lower and upper rotating pressing plates; allowing the binding agent to foam up, expand and harden between the upper and lower pressing plates. A manufacturing apparatus and a plate-like product are also indicated.
Compound 530592: 2-Bromopropionic acid, pentadecyl ester

Chemical compound data from PubChem database. IUPAC Name: pentadecyl 2-bromopropanoate. Molecular Formula: C18H35BrO2. Molecular Weight: 363.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2012 Uniform Reporting System (URS) Tables for Oklahoma

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Lack of association between estrogen receptor β dinucleotide repeat polymorphism and autoimmune thyroid diseases in Japanese patients

Background
          The autoimmune thyroid diseases (AITDs), such as Graves' disease (GD) and Hashimoto's thyroiditis (HT), appear to develop as a result of complex interactions between predisposing genes and environmental triggers. Susceptibility to AITDs is conferred by genes in the human leukocyte antigen (HLA) and genes unlinked to HLA, including the CTLA-4 gene. Recently, estrogen receptor (ER) β, located at human chromosome 14q23-24.1, was identifed. We analyzed a dinucleotide (CA)n repeat polymorphism located in the flanking region of ERβ gene in patients with AITDs and in normal subjects. High heterozygosity makes this polymorphism a useful marker in the genetic study of disorders affecting female endocrine systems. We also correlated a ERβ gene microsatellite polymorphism with bone mineral density (BMD) in the distal radius and biochemical markers of bone turnover in patients with GD in remission.
        
        
          Results
          Fourteen different alleles were found in 133 patients with GD, 114 patients with HT, and 179 controls subjects. The various alleles were designated as allele*1 through allele*14 according to the number of the repeats, from 18 to 30. There was no significant difference in the distributions of ERβ alleles between patient groups and controls. Although recent study demonstrated a significant relation between a allele*9 in the ERβ gene and BMD in postmenopausal Japanese women, there were no statistically significant interaction between this allele and BMD in the distal radius, nor biochemical markers in patients with GD in remission.
        
        
          Conclusions
          The present results do not support an association between the ERβ microsatellite marker and AITD in the Japanese population. We also suggest that the ERβ microsatellite polymorphism has at most a minor pathogenic importance in predicting the risk of osteoporosis as a complication of GD.
Managing Scope Change versus Scope Creep

This webinar, sponsored by the Children’s Bureau’s Division of State Systems, features Statewide Automated Child Welfare Information System leadership staff from four states in a panel discussion about managing project scope. Tom Kine (Minnesota), Laurie Johnson (Michigan), Colleen Mousinho (Georgia), and Susan Stockwell (Pennsylvania) define the differences between scope change and scope creep and identify strategies for planning, monitoring, and managing project scope, while discouraging or remedying scope creep.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 527365: 18,22-Dimethyl-hentriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 19,23-dimethyldotriacontanenitrile. Molecular Formula: C34H67N. Molecular Weight: 489.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Survey of Substance Abuse Treatment Services (N-SSATS-2014)

<p>The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Behavioral Health Services (I-BHS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment Facility Locator <a href="http://findtreatment.samhsa.gov">http://findtreatment.samhsa.gov</a>, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.This study has 1 Data Set.</p>
2008 NSDUH Detailed Tables

The 2008 national detailed tables for the NSDUH.  The table sections are:Highlights1. Introduction2. Illicit Drug Use3. Alcohol Use4. Tobacco Use5. Initiation of Substance Use6. Youth Prevention-Related Measures7. Substance Dependence, Abuse, and Treatment8. Mental Health9. Discussion of Trends in Substance Use among Youths and Young Adults
Mechanical ventilation in rural ICUs

Background:
          In recent years, rural hospitals have expanded their scope of
				specialized services, which has led to the development and staffing of rural
				intensive care units (ICUs). There is little information about the breadth,
				quality or outcomes of these services. This is particularly true for
				specialized ICU services such as mechanical ventilation, where little, if any,
				information exists specifically for rural hospitals. The long-term objectives
				of this project were to evaluate the quality of medical care provided to
				mechanically ventilated patients in rural ICUs and to improve patient care
				through an educational intervention. This paper reports baseline data on
				patient and hospital characteristics for both rural and rural referral
				hospitals.
        
        
          Results:
          Twenty Iowa hospitals were evaluated. Data collected on 224
				patients demonstrated a mean age of 70 years and a mean ICU admission Acute
				Physiology and Chronic Health Evaluation (APACHE) II score of 22, with an
				associated 36% mortality. Mean length of ICU stay was 10 days, with 7.7
				ventilated days. Significant differences were found in both institutional and
				patient variables between rural referral hospitals and rural hospitals with
				more limited resources. A subgroup of patients with diagnoses associated with
				complex ventilation had higher mortality rates than patients without these
				conditions. Patients who developed nosocomial events had longer mean ventilator
				and ICU days than patients without nosocomial events. This study also found ICU
				practices that frequently fell outside the guidelines recommended by a task
				force describing minimum standards of care for critically ill patients with
				acute respiratory failure on mechanical ventilation.
        
        
          Conclusions:
          Despite distinct differences in the available resources between
				rural referral and rural hospitals, overall mortality rates of ventilated
				patients are similar. Considering the higher mortality rates observed in
				patients with complicated medical conditions requiring complex ventilation
				management, the data may suggest that this subgroup could benefit from
				treatment at a tertiary center with greater resources and technology.
Provider of Services File - Internet Quality Improvement and Evaluation System

The Internet Quality Improvement and Evaluation System (iQIES) Provider of Services File (POS) includes provider demographic and associated certification information for Home Health Agency, Ambulatory Surgical Center, Hospice, Nursing Home, Organ Procurement Organization, Portable X-ray, End-Stage Renal Disease, Intermediate Care Facilities for Individuals with Intellectual Disabilities, Outpatient Physical Therapy/Speech Language Pathology and Comprehensive Outpatient Rehabilitation Facility providers. Additionally, you will find the provider number (CMS Certification Number), name, address, and other characteristics of the participating providers.
Compound 530507: 3-Cyclopentylpropionic acid, 4-hexadecyl ester

Chemical compound data from PubChem database. IUPAC Name: hexadecan-4-yl 3-cyclopentylpropanoate. Molecular Formula: C24H46O2. Molecular Weight: 366.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529624: 2-Butyl-1,3-dithiolane

Chemical compound data from PubChem database. IUPAC Name: 2-butyl-1,3-dithiolane. Molecular Formula: C7H14S2. Molecular Weight: 162.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2013 NSDUH Instrumentation Protocol Changes

The 2013 National Survey on Drug Use and Health (NSDUH) instrumentation protocols underwent several modifications from the protocols employed for the 2012 NSDUH. A summary of the changes for the 2013 NSDUH can be divided into three topics: (1) the computer-assisted interviewing (CAI) screening instrument, (2) the CAI questionnaire, and (3) the interviewer materials.